Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Designation of Prescription Drugs Proceeding as Planned: Korosho
January 24, 2005
- WEBSITE NEWS
January 24, 2005
- Full-scale Discussions on Revision of Medical Service Law to Begin in Autumn
January 24, 2005
- NEW PRODUCTS
January 24, 2005
- Opinions on Revisions of ADR, Malfunctions Reporting Criteria Sought: Korosho
January 24, 2005
- 1st 3Qtrs Business Results
January 24, 2005
- REGULATORY NEWS IN BRIEF
January 24, 2005
- Final Agreement Reached on Disclosure of Clinical Trial Information: 4 Major Drug Bodies
January 24, 2005
- JMA to Demand More Funds for Medical Services with People: Dr Uematsu
January 24, 2005
- RESEARCH & DEVELOPMENT NEWS IN BRIEF
January 24, 2005
- 2005 to Be Decisive Year for Health Insurance Reform: Kenporen
January 24, 2005
- PRESS SEMINAR
January 24, 2005
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
January 24, 2005
- OTC NEWS IN BRIEF
January 24, 2005
- New Year's Gathering of 4 Tokyo-based Associations
January 24, 2005
- MEDICAL DEVICE NEWS IN BRIEF
January 24, 2005
- Leaders Outline Strategies for Survival in New Year's Addresses
January 24, 2005
- BULLETIN
January 24, 2005
- Aventis Pharma Aims to Strengthen Allegra's Leading Position
January 24, 2005
- BULLETIN
January 24, 2005
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…